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Oral Presentations 25CIBMTR (98.5% accuracy for Chang Gung). Median pre-freeze
TNC cell dose was 10.9107/kg, and median pre-freeze CD341
cell dose was 4.0105/kg. The number of CB products HLA ABDR
matched were 4, 11, and 24 for 6/6, 5/6, and 4/6 or fewer matches.
No significant adverse events were observed during infusion despite
major ABO incompatibility in some cases and forgoing post-thaw
wash. Cumulative incidences of donor-derived (chimerism confirmed)
neutrophil (ANC500), platelet 20K and 50K (plt 20K& 50K) engraft-
ment were 96611%, 92611% and 92612%, and median times to
ANC500, plt 20K and 50K engraftment were 17.5 days (range 11–
26), 49.5 days (range 28–135) and 63.5 days (range 35–203), respec-
tively. Acute GvHD was manageable and occurred in 61611%
(Grade II-IV), and extensive chronic GvHD occurred in only
464% of the patients. Five patients expired including 1 death prior
to day 110 due to traumatic head injury. 100-day and 1-year trans-
plant related mortality were 1065% and 1366%. Overall survival
at 1 and 3 years were 8766% and 8268%, while thalassemia-free sur-
vival at 1 and 3 years were 8567%and 7869%.Mean andmedian fol-
low up times were 24 and 16 months respectively (range 0.3–58
months) as of August 2008. To our knowledge, this is the largest sin-
gle-institutional UCBT series for thalassemia, and shows the favor-
able clinical results that are attainable when TNC dose is optimized
with PD CBU, no post-thaw wash and DCT when necessary.
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TREOSULFAN IN CONDITIONING REGIMENS IN CHILDREN WITH
NON-MALIGNANT DISORDERS, INCLUDING APLASTIC ANAEMIA-HIGH
RATE OF STABLE ENGRAFTMENT AND LOW TRANSPLANT-RELATED
MORTALITY
Kalwak, K., Owoc-Lempach, J., Gorczynska, E., Porwolik, J.,
Ussowicz, M., Musial, J., Wojcik, D., Pazdzior, D., Skarzynska, M.,
Dyla, A., Chybicka, A. Wroclaw Medical University, Wroclaw, Poland
Treosulfan is an immuno-suppressive and myeloablative alkylat-
ing agent that has been introduced as a conditioning agent in hema-
topoietic stem cell transplantation (HSCT), mostly in adults with
malignancies. Recently published UK study on 32 children with
non- malignant disease showed excellent engraftment with reduced
regimen- related toxicity. We report the use of treosulfan in 26
children (median age 8.2, range 0.4–17.8; SAA n5 14, inborn errors
n5 12, incl X-ALD n5 4, SCID n5 5, CGD n5 2 and Griscelli S.
n5 1) who underwent HSCT for non- malignant disease within last
five years. Patients received a total treosulfan dose of 30 g/m2 in SAA
pts with the maximum dose of 36 or 42 g/m2 in other pts. Patients
underwent matched sibling donor HSCT (n 5 5), matched or mis-
matched unrelated donor HSCT (n 5 18) or haploidentical T-cell
depleted PBSCT (n 5 3). All pts with vSAA received a unified
protocol incl. treosulfan 30 g/m2, CY 200 mg/kg and rabbit ATG.
The rationale for the use of treosulfan were: a/ risk of rejection in
heavily pretransfused SAA patients (treosulfan added to standard
CY); b/ the risk of inflammatory flare after busulfan (Bu) -containing
regimen in CGD, GS (HLH); c/ graft rejection after RIC (FluMel-
Campath) in CGD; d/ VOD risk after Bu-containing regimen in
v.small children with SCID and e/ risk of neurotoxicity and inflam-
matory flare after Bu-containing regimens in pts with X-ALD.
Median follow-up of SAA pts was 3.2 years and 1.7 years of others.
Severe mucositis was noted in only two pts (8%) with SAA. One pa-
tient with SAA (4%) died early due to renal insufficiency. Other 4 pts
with SAA died due to sepsis, TTP complicating GvHD and CLS. In
the inborn errors group 11 out of 12 pts (92%) remain alive with sta-
ble allogeneic (in 80% of pts) or mixed chimerism, in good clinical
status except for one SCID patient with BCG-itis flare posttrans-
plant. One patient with SCID died due to pneumonia. The above
presented results seem to be particularly promising considering the
majority of alternative transplants in the series (81% of either mis-matched or matched MUD or haploidentical T-cell depleted
PBSCT). In conclusion: treosulfan-based conditioning regimens
are associated with excellent engraftment and reduced regimen-re-
lated toxicity in children with SAA and especially in children with
non- malignant disease who are at high risk for both regimen-related
toxicity and graft failure. Treosulfan is worth special consideration in
children with HLH, CGD or ALD.61
FAVORABLE OUTCOMES IN PATIENTS WITH MALIGNANT INFANTILE
OSTEOPETROSIS FOLLOWING HAPLOIDENTICAL TRANSPLANTATION
USING A REDUCED INTENSITY PREPARATIVE REGIMEN
Kasow, K.A.1, Kaste, S.C.1, Lovins, R.1, Wright, N.L.1, Leung, W.1,
Hale, G.A.1, Horwitz, E.M.2 1St. Jude Children’s Research Hospital,
Memphis, TN; 2Children’s Hospital of Philadelphia, Philadelphia, PA
Malignant infantile osteopetrosis (MIOP) is a rare autosomal re-
cessive hereditary disorder characterized by dysfunctional osteo-
clasts leading to distinctive facial features, hepatosplenomegaly,
and bone marrow failure. The only cure is HSCT, yet most do not
have a matched sibling donor. Time needed to identify a matched
unrelated donor may permit disease progression and extensive mar-
row fibrosis. Thus, alternative donors are to be considered. From
September 2004 to March 2008, we treated 5 consecutive MIOP pa-
tients (pts) using mismatched family member donors (4 were male)
on an IRB-approved prospective clinical trial designed to describe
outcomes and bone remodeling through 1 year after HSCT. The
median age at HSCTwas 0.7 years (y) (range, 0.5–1.2 y). Each pt re-
ceived a reduced intensity preparative regimen of melphalan
(140mg/m2), fludarabine (200mg/m2), thiotepa (10mg/kg), and 27
days of OKT3. G-CSF mobilized PBSC grafts were CD3-depleted
using the CliniMACS selection system; no T-cell add-back was per-
formed. GVHD prophylaxis consisted of cyclosporine. Post-pro-
cessing, grafts contained a median of 32.1  106 CD341 cells/kg
(range, 27.9–68.6  106/kg) and 6.4  104 CD31 cells/kg (range,
3.1–15.5  104/kg). Neutrophil and platelet engraftment occurred
in all at a median time of 16 days (range, 12–18 days) and 67 days
(range, 15–93 days) after HSCT. Donor chimerism is 100% by
VNTR analysis in surviving pts. No pts had Grade 3–4 acute
GVHD; 2 developed Grade 2 skin acute GVHD. Chronic
GVHD, limited to skin in 1 patient, resolved in 7 months. One pt
had mild VOD and 2 required prolonged intubation for respiratory
failure. 1 pt required a CD341 boost and a T-lymphocyte boost for
poor graft function and eventually died of secondary graft failure and
CMV pneumonitis. The other 4 are alive and well at a median of 758
days after HSCT (range, 206–1467 days), all with a Lansky score of
100 at last visit. Bone mineral density was evaluated by computed to-
mography in pts at specific time points (Table1). Hearing has been
preserved in all 4 pts. Though vision is compromised, the older 2 sur-
vivors are able to discern colors without difficulty. MIOP pts under-
going haploidentical HSCT with a reduced intensity regimen
experience rapid hematopoietic engraftment, treatable toxicity, and
bone remodeling, resulting in favorable outcomes and indicating
that this treatment plan is a feasible option for this pt cohort who
lack a matched sibling donor and require rapid HSCT.
Quantitative computed tomography (qCT) results of MIOP
patients at specific time points before and after HSCT
Pre-HSCT 2 month 4 month 6 month 9 month 12 monthMedian qCT
Z-score26.33 26.55 21.41 17.32 8.28 6.99Range 20.24-
32.5724.70-
27.7515.99-
22.7113.98-
17.337.80-
13.203.25-10.72% change
from
baselineN/A [ 0.8% Y 18.7% Y 34% Y 68.6% Y 73.4%MIOP: malignant infantile osteopetrosis; HSCT: hematopoietic stem cell
transplantation; qCT: quantitative computed tomography; N/A: not ap-
plicable.
